Ovarian Cancer

Take a look at the top five CURE stories of June 2018 in this video.

PARP inhibitors continue to impress in the ovarian cancer space, as findings from the recent phase 3 SOLO-1 trial showed that Lynparza (olaparib) showed clinically-meaningful improvement in progression-free survival (PFS) when used in the first-line maintenance setting.

Folate receptor alpha was a promising biomarker when it came to treatment with mirvetuximab soravtansine.

A recent review of data found that 79 percent of patients with ovarian cancer felt uncomfortable raising psychological and emotional concerns during their consultations.

In the QUADRA study, treatment with Zejula (niraparib) demonstrated durable responses among women with relapsed or refractory ovarian cancer, regardless of BRCA mutation.

Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

The Food and Drug Administration approved a combination of Avastin (bevacizumab) plus the chemotherapy agents carboplatin and paclitaxel, followed by Avastin alone, for the treatment of patients with advanced ovarian cancer who have had surgical resection.

The FDA approved the Paxman Scalp Cooling System for patients with solid tumors who wish to prevent chemotherapy-related hair loss.

Although genetic testing could be crucial in developing treatment plans and improving outcomes in women with ovarian and breast cancer, less than 20 percent of eligible patients actually get tested, according to Mike Janicek, M.D.

The field of ovarian cancer is changing rapidly, and moving toward an era of precision medicine.

While many advocacy groups set out to raise money for cancer research, a first-of-its-kind charitable crowdfunding platform, called Sound Affects, has set out to change how the war on cancer is fought and financed, all with support from musical talents.

There are now three PARP inhibitors approved for the treatment of ovarian cancer, improving outcomes of many of the women who take them.

Paradigms are shifting in the way that ovarian cancer is being treated.

Memorial Day has multiple meanings for this cancer survivor.

Survivors teach medical and nursing students around the world about early disease signs and symptoms.

Girls Gone Rx sponsors all-female fitness competitions to raise money for Bright Pink, a nonprofit that focuses on prevention and early detection of breast and ovarian cancer.

Palliative care can be used at all cancer stages, and can drastically improve patients' quality of life.

With the number of treatment options consistently increasing, tumor testing is growing more important to personalize care for women with ovarian cancer.

An evening of storytelling among women afflicted by ovarian cancer – whether it be their own diagnosis or a loved one’s – helped to empower individuals to find their voice.

Hear from our four Ovarian Cancer Heroes about what inspires them in the fight against the disease.

So, what was the first thing I thought about when I vowed to not think about cancer? Cancer, of course.

The Food and Drug Administration (FDA) approved a next-generation sequencing (NGS) companion diagnostic assay that can detect BRCA1/2 genetic mutations, as well as the percentage of genomic loss of heterozygosity (LOH) in patients with ovarian cancer.

Albeit growing popularity of at-home genetic testing, it is still necessary to seek professional medical opinions from genetic counselors to help discuss results.

Many patients with ovarian cancer have misconceptions about the care they will receive while on a clinical trial, according to Laurel W. Rice, M.D.